IDH2 and glioblastoma: Any degree of EGFR amplification was associated with IDH wildtype, ATRX retention, variable TERT mutation status, and absence of a 1p/19q deletion, typically in glioblastomas.27,99 We reveal the propensity for at least moderate, if not high-level, EGFR amplification to manifest with IDH wildtype glioblastoma.